The effect of adjuvant radiotherapy on overall survival in adults with intracranial ependymoma.

Background Adult intracranial ependymoma is rare, and the role for adjuvant radiotherapy (RT) is not well defined. Methods We used the National Cancer Database (NCDB) to select adults (age ≥ 22 years) with grade 2 to 3 intracranial ependymoma status postresection between 2004 and 2015 and treated with adjuvant RT vs observation. Four cohorts were generated: (1) all patients, (2) grade 2 only, (3) grade 2 status post-subtotal resection only, (4) and grade 3 only. The association between adjuvant RT use and overall survival (OS) was assessed using multivariate Cox and propensity score matched analyses. Results A total of 1787 patients were included in cohort 1, of which 856 patients (48%) received adjuvant RT and 931 (52%) were observed. Approximately two-thirds of tumors were supratentorial and 80% were grade 2. Cohorts 2, 3, and 4 included 1471, 345, and 316 patients, respectively. There was no significant association between adjuvant RT use and OS in multivariate or propensity score matched analysis in any of the cohorts. Older age, male sex, urban location, higher comorbidity score, earlier year of diagnosis, and grade 3 were associated with increased risk of death. Conclusions This large NCDB study did not demonstrate a significant association between adjuvant RT use and OS for adults with intracranial ependymoma, including for patients with grade 2 ependymoma status post-subtotal resection. The conflicting results regarding the efficacy of adjuvant RT in this patient population highlight the need for high-quality studies to guide therapy recommendations in adult ependymoma.

[1]  T. Zhou,et al.  Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[3]  G. Reifenberger,et al.  EANO guidelines for the diagnosis and treatment of ependymal tumors. , 2018, Neuro-oncology.

[4]  D. Boffa,et al.  Using the National Cancer Database for Outcomes Research: A Review , 2017, JAMA oncology.

[5]  T. Merchant Current Clinical Challenges in Childhood Ependymoma: A Focused Review. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. B. Butler,et al.  Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma , 2017, Journal of Neuro-Oncology.

[7]  R. Bindra,et al.  Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. , 2016, JAMA oncology.

[8]  K. Aldape,et al.  The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants , 2016, Acta Neuropathologica.

[9]  R. Bindra,et al.  Adjuvant chemotherapy and overall survival in adult medulloblastoma , 2016, Neuro-oncology.

[10]  T. Hortobágyi,et al.  Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Gilbert,et al.  Biology and management of ependymomas. , 2016, Neuro-oncology.

[12]  K. Black,et al.  Treatment and survival of supratentorial and posterior fossa ependymomas in adults , 2016, Journal of Clinical Neuroscience.

[13]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[14]  T. Mikkelsen,et al.  Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. , 2015, Neuro-oncology.

[15]  Li Ding,et al.  C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.

[16]  P. Austin The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[17]  B. Schatlo,et al.  A multi-center retrospective analysis of treatment effects and quality of life in adult patients with cranial ependymomas , 2013, Journal of Neuro-Oncology.

[18]  C. Gross,et al.  Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. , 2012, International journal of radiation oncology, biology, physics.

[19]  Mark R. Gilbert,et al.  Predictors of Survival among Pediatric and Adult Ependymoma Cases: A Study Using Surveillance, Epidemiology, and End Results Data from 1973 to 2007 , 2012, Neuroepidemiology.

[20]  M. Gilbert,et al.  Predictors of survival among older adults with ependymoma , 2012, Journal of Neuro-Oncology.

[21]  O. Chinot,et al.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. , 2010, Neuro-oncology.

[22]  K. Aldape,et al.  Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. , 2010, Neuro-oncology.

[23]  J. Villano,et al.  Descriptive epidemiology of ependymal tumours in the United States , 2010, British Journal of Cancer.

[24]  Kristin L. Sainani,et al.  Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. , 2009, Journal of neurosurgery.

[25]  T. Merchant,et al.  Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.